IMTX
Immatics NV
NASDAQ · Healthcare · Biotechnology · DE
$6.90
−5.58%Year over year
Reported trailing growth
- Revenue
- -68.0%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -20.2%
- Operating cash flow
- -24.7%
Forward estimates
Based on analyst estimates
- Revenue
- -22.8%
- EBITDA
- -47.9%
- EPS
- -37.6%
Three-year CAGR
- Revenue
- -34.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -0.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026